Buying Second Chances: Biossil, Theriva and the AI-Native Bet on Shelved Drugs
Dr. Dereck Mush, MD, MBA
What they do
Biossil combines AI with clinical and translational development expertise, with teams in Toronto and Boston. In a transaction closed October 30 and announced November 2, 2026, it acquired Theriva Biologics rights to SYN-004 and SYN-007 and certain SYN-006 assets. These are development-stage programs, not approved treatments.
People in this update
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI-native drug development
- Product type
- Platform software
- Stage
- Growth
- Headquarters
- Toronto, Canada
- Region
- North America
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
The senolytic drug pipeline is narrowing toward a smaller set of credible candidates
Dr. Dereck Mush, MD, MBA